VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

Shaney L Barratt, Victoria A Flower, John D Pauling, Ann B Millar

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

Original languageEnglish
Article number1269
Pages (from-to)1-17
Number of pages17
JournalInternational Journal of Molecular Sciences
Volume19
Issue number5
DOIs
Publication statusPublished - 24 Apr 2018

Fingerprint

Pulmonary diseases
lungs
Vascular Endothelial Growth Factor A
Lung Diseases
fibrosis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases
biology
interstitials
Lung
Systemic Scleroderma
homeostasis
bioavailability
pathogenesis
Biological Availability
Pneumonia
Homeostasis
Fibrosis
Therapeutics
organs

Keywords

  • Journal Article
  • Review
  • VEGF
  • Fibrosis
  • Interstitial lung disease
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Molecular Biology
  • Spectroscopy
  • Catalysis
  • Inorganic Chemistry
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. / Barratt, Shaney L; Flower, Victoria A; Pauling, John D; Millar, Ann B.

In: International Journal of Molecular Sciences, Vol. 19, No. 5, 1269, 24.04.2018, p. 1-17.

Research output: Contribution to journalReview article

@article{7bfdd00a4dce4a59bc20b26a14ef24cc,
title = "VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease",
abstract = "Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.",
keywords = "Journal Article, Review, VEGF, Fibrosis, Interstitial lung disease, Vascular endothelial growth factor",
author = "Barratt, {Shaney L} and Flower, {Victoria A} and Pauling, {John D} and Millar, {Ann B}",
year = "2018",
month = "4",
day = "24",
doi = "10.3390/ijms19051269",
language = "English",
volume = "19",
pages = "1--17",
journal = "International Journal of Molecular Sciences",
issn = "1422-0067",
publisher = "MDPI",
number = "5",

}

TY - JOUR

T1 - VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

AU - Barratt, Shaney L

AU - Flower, Victoria A

AU - Pauling, John D

AU - Millar, Ann B

PY - 2018/4/24

Y1 - 2018/4/24

N2 - Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

AB - Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

KW - Journal Article

KW - Review

KW - VEGF

KW - Fibrosis

KW - Interstitial lung disease

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85046080862&partnerID=8YFLogxK

U2 - 10.3390/ijms19051269

DO - 10.3390/ijms19051269

M3 - Review article

VL - 19

SP - 1

EP - 17

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1422-0067

IS - 5

M1 - 1269

ER -